Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This open-label, balanced, randomized, two-treatment, four-period, two-sequence, single dose,
crossover fully replicated study was conducted on fixed-dose combination of quinapril 20 mg
and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc. (division of Ranbaxy
Laboratories Limited) and Accuretic 20-25 mg tablets of Parke-Davis (division of Pfizer Inc.)
in healthy, adult, human, male, subjects under fed conditions.